September 13, 2019 / 12:14 PM / 4 days ago

Biogen scraps two late-stage Alzheimer's trials

Sept 13 (Reuters) - Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer’s disease.

The companies said the decision was based on the results of a safety review conducted by a data safety monitoring board, which recommended to discontinue the trials due to unfavorable risk-benefit ratio.

The announcement comes months after the companies said they were ending two late-stage trials of another experimental Alzheimer’s disease drug, aducanumab.

The company’s shares fell 1.6% to $228.50 in premarket trading. (Reporting by Manojna Maddipatla in Bengaluru Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below